Skip to main content
TipRanks
Go Ultimate75% OFF

Givaudan SA (GIN1) AI Stock Analysis

1 Followers
DE:GIN1

Givaudan SA

(Frankfurt:GIN1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Resilient profitability and cash generationSustained margins and strong conversion of earnings into cash indicate a durable, formulation-led business model with meaningful operating quality. This supports continued investment in innovation, customer support, and capacity while providing financial resources for dividends, debt service, and strategic growth.
Negative Factors
Elevated leverageHigher leverage reduces financial flexibility and makes the company more sensitive to slower growth, elevated rates, or weaker cash conversion. Although management expects improvement, debt remains meaningful relative to earnings and could compete with investment or shareholder-return priorities.

Givaudan SA (GIN1) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%DE:GIN1+28.97%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 44.74B
Dividend Yield
1.87%
Average Volume (3M)
107
Price to Earnings (P/E)
30.2
Beta (1Y)
0.56
Revenue Growth
0.13%
EPS Growth
-11.21%
Country
Germany
Employees
17,580
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Givaudan SA Business Overview & Revenue Model

Company Description

Founded in Vernier, Switzerland in 1796, Givaudan SA is a global leader specializing in the development, production, and supply of fragrance, beauty, taste, and wellbeing solutions for the consumer goods industry. The company operates through two cor...

Givaudan SA Earnings Call Summary

Earnings Call Date:Jul 23, 2026(Q2-2026)|% Change Since:22.38%|Next Earnings Date:Jan 27, 2027
Earnings Call SentimentNeutral

The call conveyed a balanced message: solid operational momentum (notably in Fragrance & Beauty and Asia), clear signs of sequential recovery in Taste & Wellbeing, continued investment in innovation and sustainability, and re-affirmation of medium-term 2030 targets. Offsetting these positives were material nonrecurring litigation and provision charges (CHF 103m), weaker reported net income and EPS, negative adjusted free cash flow in H1, higher net debt/leverage and elevated working capital. Management expressed confidence in normalization of working capital, improved cash generation in H2 and delivery against the 2030 strategic ambitions, but the near-term financial impacts of one-offs and regional softness leave the picture mixed.

Positive Updates

Group Sales Growth (Like-for-Like)
Group sales of CHF 3,799m in H1 2026, up 3.6% like-for-like (reported -1.7% in CHF due to Swiss franc strength). Growth was primarily volume-led and broadly balanced across customer groups and geographies.

Negative Updates

Nonrecurring Costs and Litigation Impact
Recorded CHF 103m of nonrecurring costs in H1 2026 (CHF 83m litigation settlements/provisions and CHF 20m acquisition/restructuring/project costs). Notable items: CHF 30m settlement in Fragrance & Beauty (antitrust-related) and CHF 53m provision in Taste & Wellbeing (adverse Missouri judgment on butter flavor litigation).

Company Guidance

Guidance from the call reaffirmed the 2030 targets of 4–6% like‑for‑like sales growth and an average adjusted free cash flow margin above 12% over the 2026–2030 cycle; management expects stronger cash generation in H2 after adjusted free cash flow of minus CHF119m (‑3.1% of sales) in H1, and reiterated net investment guidance of 4–5% of sales (net investments were 5.4% in H1). They signalled low single‑digit input cost inflation in H2 (with a $10 oil move ≈ 1% effect on synthetics), that partial U.S. tariff refunds will be passed back to customers in H2 (broadly offsetting inflation‑related pricing), and a continued sequential recovery in Taste & Wellbeing alongside strong momentum in Fragrance & Beauty. Financial pacing to note: H1 adjusted EBITDA CHF923m (margin 24.3% vs 25.2% prior), adjusted EPS H1 CHF60.25, net debt CHF4.6bn (net debt/EBITDA 2.8x) and net working capital 30.8% of sales (expect meaningful improvement by year‑end); management expects full‑year EBITDA to be around the mid‑24% range on current visibility.

Givaudan SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

DE:GIN1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
BCPCBCPC79Outperform$5.39B31.7113.21%0.57%9.42%16.31%
ECLECL72Outperform$84.87B41.0920.70%0.96%9.33%5.71%
IFFIFF62Neutral$19.89B105.381.41%2.01%-16.67%―
SXTSXT62Neutral$4.97B29.2613.66%1.40%9.54%21.44%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
SCLSCL55Neutral$1.50B349.050.36%2.40%10.02%-90.50%

* Basic Materials Sector Average

Performance Comparison

0%20%40%60%DE:GIN1BCPCECLIFFSXTSCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:GIN1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:GIN1Givaudan SA87.5018.1826.23%
BCPCBalchem168.7316.9411.16%
ECLEcolab300.6841.7616.13%
IFFInternational Flavors & Fragrances80.0816.9326.80%
SXTSensient117.5425.5927.83%
SCLStepan Company66.0524.6859.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.